Catalog No.
DHB74001
Description
ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O95760
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ANB020, CAS: 2022981-44-6,IL33
Clone ID
Etokimab
Efficacy of biologics in atopic dermatitis, PMID: 32003247
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis, PMID: 34213742
Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy, PMID: 31723064
Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis, PMID: 31645451
Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis, PMID: 32507066
The use of biologics in food allergy, PMID: 33966304
Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?, PMID: 31073812
Biologics in food allergy: up-to-date, PMID: 33733975
IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers? PMID: 32719677
Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity. PMID: 33023944
Phenotypic and functional translation of IL33 genetics in asthma. PMID: 32442646
IL33/ST2 Axis in Diabetic Kidney Disease: A Literature Review. PMID: 30769901
IL33 Is a Key Driver of Treatment Resistance of Cancer. PMID: 32156776
IL33 rs1342326 gene variation and allergic rhinitis. PMID: 32053215
Interleukin-33 in health and disease. PMID: 27640624
Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. PMID: 29247993
Expression of IL33 and IL35 in oral lichen planus. PMID: 29633015
Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. PMID: 32615087
IL33 rs1342326 gene variation is associated with allergic rhinitis at school age after infant bronchiolitis. PMID: 31955459
IL33 in rheumatoid arthritis: potential contribution to pathogenesis. PMID: 27692395
Tumor-Derived IL33 Promotes Tissue-Resident CD8(+) T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. PMID: 32917659
IL33 Stimulates Innate Lymphoid Cells to Recruit CD8(+) T Cells to PDACs. PMID: 32111599
IL-33/ST2 Axis in Organ Fibrosis. PMID: 30405626
Tumor-initiating cells establish an IL-33-TGF-beta niche signaling loop to promote cancer progression. PMID: 32675345
Interleukin-33 in atopic dermatitis. PMID: 31455506
ST2/IL-33 signaling in cardiac fibrosis. PMID: 31561019
Protective role of IL33 signaling in negative pregnancy outcomes associated with lipopolysaccharide exposure. PMID: 33423320
IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice. PMID: 32140881
Interleukin-33 Promotes Serotonin Release from Enterochromaffin Cells for Intestinal Homeostasis. PMID: 33220232
Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. PMID: 29420261
An intrinsic role of IL-33 in T(reg) cell-mediated tumor immunoevasion. PMID: 31844326
IL-33: biological properties, functions, and roles in airway disease. PMID: 28658560
IL-33 and the intestine: The good, the bad, and the inflammatory. PMID: 28687373
IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases. PMID: 31766607
IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PMID: 28742815
The Role of IL-33/ST2 Pathway in Tumorigenesis. PMID: 30205617
Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. PMID: 30333314
Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection. PMID: 32644975
Hyperactivity of Innate Immunity Triggers Pain via TLR2-IL-33-Mediated Neuroimmune Crosstalk. PMID: 33027646
Cellular context of IL-33 expression dictates impact on anti-helminth immunity. PMID: 33188058
Epithelial-Mesenchymal Transition in Asthma Airway Remodeling Is Regulated by the IL-33/CD146 Axis. PMID: 32793232
IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers? PMID: 32719677
For research use only. Not for human or drug use.
